MedTrace Logo

Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis

NCT04356222 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-05-27

No results posted yet for this study

Summary

The purpose of this study is to observe the clinical efficacy and safety of Durvalumab combined with intrathecal chemotherapy in non-small cell lung cancer with leptomeningeal metastasis

Conditions

Interventions

DRUG

Durvalumab

Intravenous infusion once every two weeks ,once 10mg/kg.

DRUG

methotrexate

Intrathecal chemotherapy specified dose on specified days

Sponsors & Collaborators

  • Hui Bu

    lead OTHER

Principal Investigators

  • Hui Bu · The Second Hospital of Hebei Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-30
Primary Completion
2023-06-30
Completion
2023-06-30
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04356222 on ClinicalTrials.gov